Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7539 1801

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EvaluatePharma World Preview 2014, Outlook to 2020


EvaluatePharma World Preview 2013 - Outlook to 2018

 Download EvaluatePharma World Preview 2014 Outlook to 2020

The seventh edition of EvaluatePharma's World Preview brings together many of our analyses to provide a top level insight, from the world's financial markets, into the expected performance of the industry between now and 2020.

Record breaking new drug approvals, a hefty product pipeline and dramatically improved R&D that has kept expenditure growth below sales growth proves that the industry is turning a new corner according to the latest edition of EvaluatePharma's World Preview report - view infographic here (PDF)

THE BURRILL REPORT PODCAST: Listen to Anthony Raeside, Head of Research at Evaluate, discussing World Preview 2014 at BIO 2014.

Key highlights in EvaluatePharma's World Preview 2014, Outlook to 2020 include:

  • Industry to grow, on average, 5.1% per year from 2013 to 2020
  • Quality of new drug approvals rose 43%, adds $24.4bn to US drug sales in 2018
  • Biologicals make up 52% of top 100 prescription & OTC drug sales in 2020
  • Oncology to set record high growth with 11.2% CAGR to 2020
  • Novartis top company by global drug sales in 2013, expected to remain through 2020
  • Teva Pharmaceutical leading generic drug maker in 2013

Download EvaluatePharma World Preview 2014 Outlook to 2020

Report Executive Summary

Press Release